CytoDyn Inc. (CYDY)
| Market Cap | 337.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.57M |
| Shares Out | 1.25B |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 934,135 |
| Average Volume | 1,487,121 |
| Open | 0.2900 |
| Previous Close | 0.2761 |
| Day's Range | 0.2594 - 0.2900 |
| 52-Week Range | 0.1000 - 0.4945 |
| Beta | 1.18 |
| RSI | 35.25 |
| Earnings Date | Aug 8, 2025 |
About CytoDyn
CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for th... [Read more]
Financial Performance
Financial StatementsNews
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial
CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer
Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health Enrollment is now underway across multiple clinical sites, in partnership with Syneos Health
A Penny Stock To Watch In Challenging Cancer Space
We have a $2.75 Price Target on CytoDyn (CYDY) in the Next 6 to 12 Months. The stock’s current price is around $0.32. CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leron...
CytoDyn Releases ESMO Breast Cancer Meeting Poster
VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...
CytoDyn highlights potential of lead drug against solid tumors with new data
CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors
Survival observations in mTNBC patients correlated with increased PD-L1 expression Preliminary evidence suggests leronlimab has potential to turn “cold” tumors “hot” VANCOUVER, Washington, May 13, 202...
CytoDyn appoints Robert Hoffman as CFO
Robert E. Hoffman joins CytoDyn as CFO starting May 2025, bringing extensive biotech leadership experience.
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer
VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...
CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany
Dr. Jacob Lalezari, CEO, and Dr. Richard Pestell, Lead Consultant in Preclinical and Clinical Oncology, to lead CytoDyn group in attendance
March 2025 Letter to Shareholders
VANCOUVER, Washington, March 18, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As envisioned, 2025 is unfolding to be an exciting year for CytoDyn Inc. (“CytoDyn” or the “Company”). On February 24, 2025...
CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab
VANCOUVER, Washington, Feb. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories
VANCOUVER, Washington, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
December 2024 Letter to Shareholders
VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc. (“CytoDyn” or the “Company”) achieved multiple crucial milestones, and loo...
CytoDyn Phase 2 study of leronlimab cleared by FDA
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
VANCOUVER, Washington, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
VANCOUVER, Wash., Oct. 30, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for mul...
CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
Abstract to be presented at the 5 th annual HIV Research for Prevention Conference Study results highlight potential for treatment VANCOUVER, Washington, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc....
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
VANCOUVER, Washington, Oct. 04, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
VANCOUVER, Washington, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential f...
September 2024 Letter to Shareholders
VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. (“CytoDyn” or the “Company”).
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
VANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...
CytoDyn Announces Settlement with Amarex Clinical Research LLC
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company's balance sheet
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...